Teva plans to take over major chunk of migraine market
Teva turns up its ambitions for migraine drug Ajovy, which is taking over a larger part of the US market than initially stated.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
In future years, more US patients will start treatment with Teva's migraine drug Ajovy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
